Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1636 1656
This examiner grants 56% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17257796 | RETROTRANSPOSON-BASED DELIVERY VEHICLE AND METHODS OF USE THEREOF | Non-Final OA | The Regents of the University of California |
| 18420013 | METHOD FOR DIAGNOSING DRUG ADDICTION, METHOD FOR SCREENING THERAPEUTIC AGENT FOR DRUG ADDICTION AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DRUG ADDICTION | Final Rejection | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17628361 | CHIMERIC MOLECULE, PHARMACEUTICAL COMPOSITION, METHOD FOR CLEAVING TARGET NUCLEIC ACID, AND KIT FOR TARGET NUCLEIC ACID CLEAVAGE OR DIAGNOSIS | Final Rejection | TOHOKU UNIVERSITY |
| 18040503 | MODULATION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) EXPRESSION | Non-Final OA | NATIONAL UNIVERSITY OF SINGAPORE |
| 19054584 | Linear DNA with Enhanced Resistance Against Exonucleases | Non-Final OA | 4BASEBIO UK LTD |
| 16735146 | Multiplex Guide RNAS | Non-Final OA | The General Hospital Corporation |
| 17788519 | IMMUNOTHERAPY FOR DIRECT REPROGRAMMING OF CANCER CELLS INTO IMMUNE CELLS/ANTIGEN PRESENTING CELLS/DENDRITIC CELLS | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18094695 | OLIGONUCLEOTIDES FOR MECP2 MODULATION | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 17658957 | LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY | Non-Final OA | Medizinische Hochschule Hannover |
| 17378274 | HUMAN MIRNAS FOR USE IN DIAGNOSIS, PROGNOSIS, AND THERAPY OF HUMAN CONDITIONS AND DISEASES | Non-Final OA | THOMAS JEFFERSON UNIVERSITY |
| 18409684 | PAPN MUTANT, METHOD FOR SITE-DIRECTED MODIFICATION OF PAPN GENE AND USE THEREOF | Non-Final OA | AGSINO GENSOURCES CO., LTD. |
| 17576971 | LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) ANALYSIS FOR PATHOGENIC TARGETS | Non-Final OA | Raytheon BBN Technologies, Corp. |
| 17430274 | COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASE TYPE 1A | Non-Final OA | BEAM THERAPEUTICS INC. |
| 18551817 | COMPOSITIONS AND METHODS FOR TREATING HYPERCHOLESTEROLEMIA | Non-Final OA | EmendoBio Inc. |
| 17497725 | NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS | Non-Final OA | ARBOR BIOTECHNOLOGIES, INC. |
| 16848117 | METHOD, LYSIS SOLUTION AND KIT FOR SELECTIVELY DEPLETING ANIMAL NUCLEIC ACIDS IN A SAMPLE | Non-Final OA | QIAGEN GMBH |
| 18157305 | USE OF STAT4 INHIBITORS FOR PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE | Final Rejection | New York Medical College |
| 17413297 | ANELLOSOMES FOR DELIVERING PROTEIN REPLACEMENT THERAPEUTIC MODALITIES | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS V, INC. |
| 17599463 | NANOSYSTEM BASED ON MICRORNA FOR TREATING OBESITY | Final Rejection | UNIVERSIDAD DE SEVILLA |
| 17094718 | METHODS AND COMPOSITIONS FOR NUCLEOSIDE TRIPHOSPHATE AND RIBONUCLEIC ACID PRODUCTION | Non-Final OA | GreenLight Biosciences, Inc. |
| 18163333 | mRNA VACCINE DESIGN USING MULTIPLE INTERACTING IMMUNO-STIMULATORY PATHWAYS, FOR CANCER AND INFECTIOUS DISEASES | Final Rejection | MicroVAX, LLC |
| 18018089 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NIEMANN-PICK TYPE C1 DISEASE | Non-Final OA | Voyager Therapeutics, Inc |
| 17311271 | MODIFIED PROTEINS AND ASSOCIATED METHODS OF TREATMENT | Final Rejection | Arcturus Therapeutics, Inc. |
| 16802678 | GENE THERAPY COMPOSITION FOR USE IN DIABETES TREATMENT | Final Rejection | Universitat Autònoma de Barcelona |
| 17986020 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF OTOFERLIN (OTOF) | Non-Final OA | Korro Bio, Inc. |
| 17788524 | BODY FAT REDUCING AGENT AND METHOD FOR SCREENING FOR SUBSTANCE CAPABLE OF REDUCING BODY FAT | Non-Final OA | INNATE CELL THERAPY INC. |
| 17678311 | COMPOSITIONS AND METHODS FOR MODULATING ATAXIN 3 EXPRESSION | Non-Final OA | ACADEMISCH ZIEKENHUIS LEIDEN |
| 17495266 | CANCER-SPECIFIC MOLECULES AND METHODS OF USE THEREOF | Final Rejection | Envisagenics, Inc. |
| 17420347 | mRNA-BASED BIOMARKERS FOR ANTIBODY-MEDIATED TRANSPLANT REJECTION | Final Rejection | LE CENTRE HOSPITALIER ET UNIVERSITAIRE DE LIMOGES |
| 17289590 | COMPOSITIONS AND METHODS FOR MODULATING EGG DEVELOPMENT IN MOSQUITOES | Final Rejection | Arizona Board Regents on Behalf of the University of Arizona |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy